Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures

References

• Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology40(8), 1163–1170 (1990).
   PubMedGoogle Scholar
• Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia42(10), 1255–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5), 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia48(7), 1308–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev.13(1), 21–42 (2007).
   PubMedGoogle Scholar
• Errington AC, Coyne L, Stöhr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology50(8), 1016–1029 (2006).
   PubMed Web of Science ®Google Scholar
• Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol.3(1), 157–169 (2008).
   Google Scholar
• Kuo CC. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol. Pharmacol.4, 712–721 (1998).
   Google Scholar
• Rudy B. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance. J. Physiol.283, 1–21 (1978).
   PubMedGoogle Scholar
• Jung HY, Mickus T, Spruston N. Prolonged sodium channel inactivation contributes to dendritic action potential attenuation in hippocampal pyramidal neurons. J. Neurosci.17(17), 6639–6646 (1997).
   PubMed Web of Science ®Google Scholar
• Mickus T, Jung HY, Spruston N. Slow sodium channel inactivation in CA1 pyramidal cells. Ann. NY Acad. Sci.868, 97–101 (1999).
   PubMedGoogle Scholar
• Yoshimura T, Arimura N, Kaibuchi K. Signaling networks in neuronal polarization. J. Neurosci.26(42), 10626–10630 (2006).
   PubMedGoogle Scholar
• Freitag J, Beyreuther BK, Heers C, Stöhr T. Lacosamide interacts with collapsin response mediator protein 2 (CRMP-2). Presented at: 11th Congress of the European Federation of Neurological Societies. Brussels, Belgium, 22–28 August 2008.
   Google Scholar
• Cavazos JE, Cross DJ. The role of synaptic reorganization in mesial temporal lobe epilepsy. Epilepsy Behav.8(3), 483–493 (2006).
   PubMed Web of Science ®Google Scholar
• Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res.2(3), 145–181 (1988).
   PubMed Web of Science ®Google Scholar
• Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res.47(3), 217–227 (2001).
   PubMed Web of Science ®Google Scholar
• Stöhr T, Kupferberg HJ, Stables JP et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res.74(2–3), 147–154 (2007).
   PubMed Web of Science ®Google Scholar
• Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res.67(1–2), 81–87 (2005).
   PubMed Web of Science ®Google Scholar
• Brandt C, Heile A, Potschka H, Stoehr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia47(11), 1803–1809 (2006).
   PubMed Web of Science ®Google Scholar
• Hovinga CA. SPM-927 (Schwarz Pharma). IDrugs6(5), 479–485 (2003).
   PubMed Web of Science ®Google Scholar
• Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia45(Suppl. 7), 307 (2004).
   Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res.61(1–3), 1–48 (2004).
   PubMed Web of Science ®Google Scholar
• Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia43(Suppl. 7), 188 (2002).
   Google Scholar
• Schiltmeyer B, Cawello W, Kropeit D, Hammes W, Horstmann R. Pharmacokinetics of the new antiepileptic drug lacosamide in human subjects with different age and gender. Presented at: 58th Annual Meeting of the American Epilepsy Society. New Orleans, LA, USA, 3–7 December 2004.
   Google Scholar
• Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia45(Suppl. 7), 123–124 (2004).
   Web of Science ®Google Scholar
• Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia49(3), 418–424 (2008).
   PubMed Web of Science ®Google Scholar
• Krauss G, Ben Menachem E, Mameniskiene R, Vaiciene N, Rudd D, Brock M. Lacosamide: safety and tolerability of adjunctive intravenous lacosamide as short-term replacement for oral lacosamide in subjects with partial-onset seizures during 30-, 15-, and 10-minute infusions. Eur. J. Neurol.14(Suppl. 1), 319–320 (2007).
   Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res.73(1), 1–52 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R. Lacosamide has low potential for drug–drug interaction. Presented at: 8th European Congress on Epileptology. Berlin, Germany, 21–25 September 2008.
   Google Scholar
• Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res.47(1–2), 17–25 (2001).
   PubMedGoogle Scholar